INCA033989 for Essential Thrombocythemia

(EXCALIBUR-ET2 Trial)

This trial tests a new treatment called INCA033989, an experimental therapy for individuals with essential thrombocythemia—a condition where the body produces too many platelets—who have a specific gene mutation known as CALR. The study compares this new treatment to the best available therapies currently in use. It targets individuals who have tried at least one other medication to control their platelet levels but still require better results. Participants should not have experienced other blood cancers or major bleeding issues in the past three months. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to potentially groundbreaking treatment advancements.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that INCA033989 maintains a good safety record from previous studies. No severe side effects required dose reduction. Most patients with essential thrombocythemia, a condition causing an excess of blood cells, tolerated the treatment well. However, some patients experienced mild to moderate side effects. In one study, 52% of patients experienced severe anemia, a significant drop in red blood cells, and 30% had a major decrease in platelet count. While these effects are serious, they were not common for everyone. Overall, INCA033989 appears well-tolerated, with manageable side effects for most individuals.¹²³⁴⁵

Unlike the standard treatments for essential thrombocythemia, such as hydroxyurea or anagrelide, INCA033989 is administered intravenously and targets the condition differently. This new drug is unique because it potentially offers a novel mechanism of action that could improve effectiveness or reduce side effects compared to existing therapies. Researchers are particularly excited about INCA033989's potential to provide better management of platelet counts, offering hope for improved patient outcomes.

Research indicates that INCA033989, one of the treatments studied in this trial, shows promise for treating essential thrombocythemia, especially in patients with a CALR mutation. In studies, 87% of patients experienced an improvement in their blood cell counts, with 70% seeing their blood counts return to normal. Improvements often appeared quickly, usually within about two weeks. Additionally, INCA033989 proved effective at higher doses, with 86% of patients showing significant improvement. These findings suggest that INCA033989 could be a good option for managing essential thrombocythemia. Participants in this trial may receive either INCA033989 or the Best Available Therapy (BAT), as selected by the investigator.⁶⁷⁸⁹¹⁰